V Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

V Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-100	Closed	-$5K	–	526
2017 Q2	$5K	Buy	+100	New	+$4.85K	﹤0.01%	661

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

V Wealth Advisors's NBIX Position: Q3 2017 in Review

V Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 100 shares — an estimated $5K sold.

V Wealth Advisors first reported a position in NBIX in Q2 2017 and held it in 1 quarter. The position peaked at $5K in Q2 2017. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

V Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 100 Neurocrine Biosciences shares in Q3 2017, an estimated $5K.
V Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Neurocrine Biosciences position peaked at $5K in Q2 2017.
223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.